Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say “exceeded expectations.”
N.J. deli stock fraud defendant behind bars as feds reveal he renounced U.S. citizenship
Three men, including Peter Coker Jr. and his dad, are accused of pumping up the stock price of a New Jersey deli-owning company once valued at $100 million.
Citi lays out the possible outcomes for First Republic after banking crisis
The San Francisco-based bank is down about 90% year to date.
Nevada approves $333 million natural gas plant as historic drought pressures state’s power grid
The natural gas-fired turbines are designed to address peak electricity demand during hot summer months and prolonged wildfire seasons.
TikTok CEO says China-based ByteDance employees still have access to some U.S. data
TikTok CEO Shou Zi Chew told U.S. lawmakers that China-based employees at its parent company ByteDance may still have access to some U.S. data from the app.
Judge cites Trump’s past verbal attacks in using anonymous jury for rape defamation case
Donald Trump is being sued for allegedly raping and defaming the writer E. Jean Carroll, who says he attacked her in a New York department store.
TikTok CEO set for grilling in House hearing. But U.S. lawmakers also face questions
While TikTok’s CEO will be in the hot seat, lawmakers will also face difficult questions about how best to deal with potential harms from tech firms.
Orange County dismisses domestic violence charges against ‘Rick and Morty’ co-creator Justin Roiland
In a statement to NBC News, an attorney for Roiland said the Orange County District Attorney’s Office conducted a “thorough review of the facts.”
Barclays says shares of this mall operator could rebound 20% because of its high income customers
The firm said the stock is at an attractive entry point given the firm’s compelling growth and demographics.
This little-known biotech stock developing treatments for blood disorders could jump 80%, BMO says
The firm initiated coverage of this stock with an outperform rating and a $40 price target.
